0001209191-18-021318.txt : 20180322
0001209191-18-021318.hdr.sgml : 20180322
20180322175813
ACCESSION NUMBER: 0001209191-18-021318
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180321
FILED AS OF DATE: 20180322
DATE AS OF CHANGE: 20180322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Went Gregory T
CENTRAL INDEX KEY: 0001604541
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36399
FILM NUMBER: 18707844
MAIL ADDRESS:
STREET 1: C/O ADAMAS PHARMACEUTICALS, INC.
STREET 2: 2200 POWELL ST, STE 220
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adamas Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001328143
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 421560076
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 750
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 510-450-3554
MAIL ADDRESS:
STREET 1: 1900 POWELL ST., SUITE 750
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: NeuroMolecular Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050524
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-03-21
0
0001328143
Adamas Pharmaceuticals Inc
ADMS
0001604541
Went Gregory T
C/O ADAMAS PHARMACEUTICALS, INC.
1900 POWELL ST., SUITE 750
EMERYVILLE
CA
94608
1
1
0
0
Chief Executive Officer
Common Stock
2018-03-21
4
S
0
4541
25.75
D
182610
D
Common Stock
195392
I
By Trust
Common Stock
80000
I
Gregory T. Went & Marjorie S. Went ttees 2012 Irr Trust FBO Bridget Elise Went
Common Stock
80000
I
Gregory T. Went & Marjorie S. Went ttees 2012 Irr Trust FBO Cora Margaret Went
Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
The shares were sold at prices ranging from $25.66 to $25.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/Jennifer Rhodes, as Attorney-in-fact
2017-03-22